Andor Health vs Becton Dickinson

Side-by-side comparison of AI visibility scores, market position, and capabilities

Becton Dickinson leads in AI visibility (80 vs 34)
Andor Health logo

Andor Health

EmergingHealthTech

Clinical Intelligence

Andor Health uses AI to synthesize patient data into real-time clinical intelligence that streamlines care team communication and coordination across EHR-connected workflows.

AI VisibilityBeta
Overall Score
D34
Category Rank
#584 of 596
AI Consensus
76%
Trend
stable
Per Platform
ChatGPT
30
Perplexity
36
Gemini
31

About

Andor Health's ThinkAndor platform applies AI to patient data from EHRs, remote monitoring devices, and clinical notes to surface actionable intelligence at the point of care — alerting teams to deteriorating patients, surfacing relevant history during handoffs, and automating documentation that currently requires manual clinical effort. The platform integrates with major EHRs including Epic and Cerner, embedding intelligence into the workflows clinicians already use rather than requiring them to access a separate application.

Full profile
Becton Dickinson logo

Becton Dickinson

LeaderHealthcare Tech

Enterprise

Franklin Lakes NJ medical technology (NYSE: BDX) at $21.8B FY2025 revenue (+8.2%); $17.5B Reverse Morris Trust spinoff with Waters (2025), Edwards critical care acquisition $4.2B (2024) competing with Baxter for infusion systems.

AI VisibilityBeta
Overall Score
A80
Category Rank
#19 of 596
AI Consensus
77%
Trend
stable
Per Platform
ChatGPT
77
Perplexity
83
Gemini
85

About

Becton, Dickinson and Company (BD) is a Franklin Lakes, New Jersey-based global medical technology company — publicly traded on the New York Stock Exchange (NYSE: BDX) as an S&P 500 Health Care component — manufacturing and selling medical supplies, devices, laboratory equipment, and diagnostic products through approximately 74,000 employees serving healthcare institutions, clinical laboratories, pharmaceutical companies, and life science researchers in over 190 countries. In fiscal year 2025 (ended September 30, 2025), BD reported full-year revenue of $21.8 billion (up 8.2% year-over-year) with Q4 FY2025 revenue of $5.9 billion (+8.3% reported, +3.9% organic growth), and declared a quarterly dividend of $1.05 per share (+1%). Founded in 1897 in New York City by Maxwell Becton and Fairleigh Dickinson Sr. as a thermometer and surgical instrument maker, BD has grown through 125+ years of acquisitions to become a Fortune 500 ($21.8B revenue, #211 on 2024 Fortune 500) global medtech leader. The company operates through three segments: BD Medical (~50% of revenue, IV catheters, syringes, prefillable drug delivery systems, and medication management solutions), BD Life Sciences (flow cytometry, microbiology, molecular diagnostics, and lab automation), and BD Interventional (advanced patient monitoring, interventional cardiology, and peripheral vascular interventions). BD invests $1.2+ billion annually in R&D. In 2024, BD acquired Edwards Lifesciences' critical care monitoring unit for $4.2 billion.

Full profile

AI Visibility Head-to-Head

34
Overall Score
80
#584
Category Rank
#19
76
AI Consensus
77
stable
Trend
stable
30
ChatGPT
77
36
Perplexity
83
31
Gemini
85
39
Claude
85
37
Grok
78

Key Details

Category
Clinical Intelligence
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Andor Health
Clinical Intelligence

Integrations

Only Becton Dickinson
Becton Dickinson is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.